NCT00638937 2018-08-29
AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
AstraZeneca